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Abstract
Emerging evidence suggests that autoimmune processes are implicated in the
pathogenesis of chronic obstructive pulmonary disease (COPD). In this study, we
assessed the expression of B-cell activating factor (BAFF) in smokers, and investi-
gated the functional importance of BAFF in the induction and maintenance of
cigarette smoke-induced pulmonary antinuclear antibodies (ANA) and tertiary
lymphoid tissues (TLTs) using a preclinical mouse model. We observed that BAFF
levels were elevated in smokers and mice exposed to cigarette smoke. In mice,
BAFF expression was rapidly induced in the lungs following 4 days of cigarette
smoke exposure and remained elevated following 8 and 24 weeks of exposure.
Alveolar macrophages were the major source of BAFF. Blockade of BAFF using a
BAFF receptor-Fc (BAFFR-Fc) construct prevented pulmonary ANA and TLT
formation when delivered concurrent with cigarette smoke exposure. Under these
conditions, no impact on lung inflammation was observed. However, administra-
tion of BAFFR-Fc following smoking cessation markedly reduced the number of
TLTs and ANA levels and, of note, reduced pulmonary neutrophilia. Altogether,
this study shows for the first time a central role of BAFF in the induction and
maintenance of cigarette smoke-induced pulmonary ANA and suggests that BAFF
blockade following smoking cessation could have beneficial effects on persistent
inflammatory processes.
In this study, we assessed the expression of B-cell activating factor (BAFF) in smok-
ers, and investigated the functional importance of BAFF in the induction and
maintenance of cigarette smoke-induced pulmonary antinuclear antibodies (ANA)
and tertiary lymphoid tissues (TLTs) using a preclinical mouse model. Data pre-
sented show that BAFF plays a central role in the induction and maintenance of
cigarette smoke-induced pulmonary ANA and suggest a therapeutic potential for
BAFF blockade in limiting autoimmune processes associated with smoking.
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
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Introduction
Cigarette smoking is the main cause of chronic obstruc-
tive pulmonary disease (COPD), a degenerative lung
disease with significant impact on pulmonary and car-
diovascular health resulting in low quality of life and
mortality (Mannino 2002; Hogg 2004; Reardon et al.
2006; Curtis et al. 2007). It is widely accepted that
chronic inflammation contributes to the pathogenesis of
COPD. Most research, to date, has focused on the
innate immune system and the contribution of media-
tors released by inflammatory cells, such as macro-
phages and neutrophils, to airflow obstruction and
alveolar destruction (Abboud and Vimalanathan 2008).
Recently, there is emerging interest in the role of the
adaptive immune system in the pathogenesis of COPD.
Autoimmune features, such as the presence of systemic
autoantibodies, as well as clonal expansion of lung CD4
and CD8 T cells, have been observed in COPD patients
and preclinical models of cigarette smoke-induced
inflammation (Lee et al. 2007; Motz et al. 2008;
Brandsma et al. 2010; Morissette et al. 2014). We
recently reported the presence of broad-spectrum
autoantibodies recognizing antinuclear antigens in the
lungs of mice exposed to cigarette smoke; a phe-
nomenon linked with the presence of tertiary lymphoid
tissues (TLTs) (Morissette et al. 2014).
B-cell activating factor (BAFF) encoded by the gene tn-
fsf13b is a member of the tumor necrosis factor ligand
superfamily and is instrumental to B-cell homeostasis and
activation (Mackay and Schneider 2009). It binds to three
receptors: TACI (tnfrsf13b), BCMA (tnfrsf17), and BAFF-
R (tnfrsf13c), which are mainly expressed by B cells at dif-
ferent developmental stages (Mackay and Schneider
2009). High circulating levels of BAFF have been linked
to autoimmune diseases such as systemic lupus erythe-
matosus (SLE), where it is suggested to cause B-cell
hyperactivity and facilitate antinuclear autoantibody
(ANA) production (Liu and Davidson 2011). Polverino
et al. (2010, 2015) previously showed that BAFF was
highly expressed in pulmonary macrophages and B cells
of COPD patients compared to healthy controls. Simi-
larly, Seys et al. (2015) reported increased expression of
BAFF in the lungs of COPD patients and cigarette
smoke-exposed mice, and that blocking BAFF decreased
lung inflammation and tissue destruction in cigarette
smoke-exposed mice.
The main objective of this study was to investigate the
role of BAFF in the cigarette smoke-induced formation
and persistence of pulmonary TLTs, and the associated
increase in ANAs, in a preclinical model of cigarette
smoke exposure. We report that levels of BAFF were
increased following short-term smoke exposure, and
remained elevated following chronic exposure to cigarette
smoke. BAFF blockade attenuated pulmonary TLT and
ANA formation when administered during smoke expo-
sure as well as during smoking cessation. Our study
shows a critical role of BAFF in smoking-induced forma-
tion of TLTs and ANA and suggests a therapeutic poten-
tial for BAFF blockade in limiting autoimmune processes
associated with smoking.
Methods
Human samples and analysis of BAFF
expression
Messenger RNA levels of tnfsf13b (BAFF) were investi-
gated using array analysis in the LAVAL gene expression
cohort (Bosse et al. 2012). BAFF protein levels were
assessed in the bronchoalveolar lavage fluid (BALF) of
cancer-free nonsmokers and active smokers (Nonsmokers
group: 5 males/5 females; aged 49  10 years old; FEV1
104  15% predicted; FVC 108  11% predicted –
Active smokers group: 3 males/1 female; aged
60  2 years old; FEV1 99  6% predicted; FVC
114  7% predicted (data are shown as mean  SD)).
Samples were obtained from the Tissue Bank of the Res-
piratory Research Network of the “Fonds de Recherche
du Quebec en Sante” (FRQS) at the “Institut universitaire
de Cardiologie et de Pneumologie de Quebec” (IUCPQ,
Laval University, Quebec City, Canada). BALF samples
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were concentrated using 3K 4 mL Amicon inserts (EMD
Millipore, Billerica, MA), and BAFF levels were measured
by sandwich ELISA according to the manufacturer’s
instructions (R&D Systems, Minneapolis, MN). BAFF
levels for each sample were normalized to total BALF pro-
tein levels as measured with the DC protein assay (Bio-
Rad, Mississauga, ON, CA).
Animals, cigarette smoke exposure, and
BAFF blockade
Six- to eight–week-old female BALB/c mice (Charles
River, Montreal, Quebec, Canada) were exposed to
cigarette smoke using a whole body exposure system
(SIU48; Promech Lab Inc., Vintrie, Sweden) as
described previously (Botelho et al. 2010; Morissette
et al. 2014). Briefly, mice were exposed twice daily to
twelve 3R4F reference cigarettes (Center for Tobacco
Reference Products, University of Kentucky, KY), with
filters removed, for 5 days per week (Monday–Friday).
Control mice were exposed to room air. BAFF blockade
was performed by injecting mice intraperitoneally with
B-cell activating factor receptor-Fc (BAFFR-Fc) (pro-
vided by MedImmune LLC, Gaithersburg, MD) or iso-
type control (500 lg in PBS) every Monday and
Thursday prior to the first cigarette smoke exposure.
Timing and duration of BAFFR-Fc administration are
described in detail in the results section and figure
legends. Mice were housed in a 12-h light–dark cycle
with food and water ad libitum. All animal protocols
were approved by the McMaster University Animal
Research Ethics Board (AREB).
Sample collection and processing
Lungs
Mice were anesthetized with isoflurane prior to being
killed via exsanguination. Following removal of the
lungs from the chest cavity, the left lung (multilobe)
was tied off and the right lung (single lobe) was
lavaged twice with 250 lL followed by 200 lL of ice-
cold PBS to collect the bronchoalveolar lavage (BAL).
Lobes of the left lung were then dissected and snap-fro-
zen prior to inflation of the right lung with 10% for-
malin at a constant pressure of 30 cm H2O. BAL cell
counts were determined using a hemocytometer prior
to centrifugation at 500 g for 10 min. Supernatants
(BALF) were kept at 80°C and the cell pellet was
used to prepare cytospins to assess cell differentials (at
least 300 cells counted per cytospin). Formalin-inflated
lungs were washed in ethanol and embedded in paraffin
blocks for histological analysis.
Pulmonary macrophage isolation and cell culture
Mice were anesthetized with isoflurane prior to being killed
via exsanguination. Whole lungs were lavaged five times with
1 mL of sterile ice-cold PBS. Cells were counted and resus-
pended in culture media (RPMI 1640, 10% FBS, 2 mmol/L
L-glutamine, 1% penicillin/streptomycin) at a concentration
of 5 9 105 macrophages per mL. We previously reported
that >90% of cells in the BAL of smoke-exposed mice are
macrophages (Gaschler et al. 2008). In a standard protocol
that yields alveolar macrophages in excess of 95% purity
(Holt 1979), 5 9 104 macrophages per well were added to a
96-well plate and incubated at 37°C (5% CO2) for 2 h to
adhere. Wells were washed with cold PBS three times to
remove nonadherent cells, including granulocytes and lym-
phocytes, and then macrophages were lysed using RIPA lysis
buffer. Lysates were collected and stored at 80°C.
Lung and spleen B-cell isolation and IgM
secretion assay
B cells were isolated from the lungs and spleens of 6–8 week-
old BALB/c mice (Charles River). Lungs were minced in a
digestion buffer (HBSS containing 0.75 mg/mL of collage-
nase A) incubated at 37°C for 1 h. Spleens were crushed
between the frosted ends of two glass slides in ice-cold PBS.
Lung and spleen single-cell suspensions were generated using
40 lm cell strainers. B cells were isolated using EasySepTM
Mouse B Cell Isolation Kit (STEMCELL Technologies Inc.,
Vancouver, British Columbia, Canada). B-cell purities of
45% and 95% for lung and spleen (CD45pos/CD19pos/
CD3neg), respectively, were achieved (data not shown).
105 cells/well were cultured in 96-well plates in 100 lL
RPMI, supplemented with 10% FBS, 2 mmol/L L-glutamine,
1% penicillin/streptomycin, 0.1% b-mercaptoethanol. Cells
were stimulated with mouse recombinant BAFF (R&D sys-
tems) or vehicle (PBS) for 72 h. Culture supernatants were
collected and IgM levels assessed by ELISA according to the
manufacturer’s specifications (eBiosciences, San Diego, CA).
Assessment of mouse BAFF and antinuclear
autoantibodies in BAL fluid
Mouse BAFF (R&D Systems) as well as antinuclear
autoantibody (ANA) (Alpha Diagnostics Intl. Inc., San
Antonio, TX) levels were assessed in the BAL fluid by
ELISA according to the manufacturer’s specifications.
Western blot analysis of BAFF in lung tissue
and pulmonary macrophage lysates
Lung lobes were homogenized in RIPA lysis buffer with a
Polytron homogenizer (Kinematica, Luzern, Switzerland).
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Total protein concentrations of pulmonary macrophages
and lung lysates were determined with the DC protein assay
(Biorad, Mississauga, Ontario, Canada). Lysates were resus-
pended in loading buffer and 15 lg (macrophage) and
40 lg (lung) of proteins were loaded per well. SDS-PAGE
was performed using 10% acrylamide gels and transferred
onto nitrocellulose membranes. Membranes were blocked
for 1 h (5% fat-free milk, 0.5% Tween-20 in PBS) and
incubated overnight with rabbit IgG anti-mouse BAFF
(1:1000; Abcam, Cambridge, United Kingdom) and goat
IgG anti-mouse b-actin (1:4000; Abcam) at 4°C. Anti-rab-
bit IgG coupled to IRdye 800 nm and anti-goat IgG cou-
pled to IRdye 700 nm were used as detection antibodies
(1:5000, LI-COR Bioscience, Lincoln, NE). Staining was
visualized with the Odyssey CLx Imager (LI-COR Bio-
science). Band intensity was quantified with the Image Stu-
dio Lite software (LI-COR Bioscience) and reported as
BAFF intensity over b-actin intensity for every sample.
Immunohistochemistry analysis of BAFF and
B-cell localization, and pulmonary TLT
assessment
BAFF and B-cell (B220) detection by immunohistochemistry
(IHC) was performed on formalin-fixed, paraffin-embedded
mouse lung sections. Briefly, lung sections (3 lm) were
deparaffinized in xylene and rehydrated in ethanol:water.
Endogenous peroxidases were blocked in 3% H2O2 in metha-
nol. Citrate buffer antigen retrieval was performed (45 min).
Sections were blocked with 1% swine serum in Tris-buffered
saline (TBS) with 0.01% Tween 20. Sections were stained
with a rabbit IgG anti-mouse BAFF (1:50; Abcam) or a rabbit
IgG anti-mouse B220 (1:100, Abcam) at 4°C overnight. Pri-
mary antibody was detected with a biotinylated goat anti-
rabbit IgG (1:100; 1 h RT) followed by a 30 min incubation
with streptavidin-Horse Radish Peroxidase (Dako, Glostrup,
Denmark). Staining was visualized using 3-amino-9-ethylcar-
bazole (AEC). Pulmonary TLTs were assessed based on mor-
phology as previously described (Morissette et al. 2014).
Briefly, three photos at a 16x magnification were taken for
every lung at two different cross-sections. Whole lung cross-
section area (Lungarea [pixel
2/1010]), as well as the number of
bronchus-associated TLT (TLTnumber), were determined
using Image J Software (https://imagej.nih.gov/ij/index.html)
and identified according to their distinctive morphology.
Data are expressed as bronchus-associated TLTs per lung
area (TLTnumber/Lungarea).
Analysis of lung and spleen B- and T-cell
population
Two lung lobes per mouse and the spleen were processed as
described in the Methods section under “Sample collection
and processing” and “Lung and spleen B-cell isolation and
IgM secretion assay” to obtain a single-cell suspension. The
lung and spleen single-cell suspensions were assessed for B
cell (CD45pos CD3neg CD19pos), CD4 T cell (CD45pos CD3pos
CD4pos CD8neg), and CD8 T cell (CD45pos CD3pos CD4neg
CD8pos) populations. Flow cytometry was performed using a
BD FACS LSR II (BD Biosciences, Mississauga, Ontario, CA)
and the analysis using FlowJo software (Ashland, OR).
Statistical analysis
Statistical differences were assessed using unpaired Stu-
dent’s t-test (2 groups) or one-way analysis of variance
(ANOVA) (>2 groups) followed by a post hoc comparison
using a Bonferroni correction for multiple comparisons.
Tests were performed using GraphPad Prism (La Jolla, CA).
Results
Cigarette smoke exposure induces BAFF
expression in the lungs of humans and mice
Increased BAFF expression has been reported previously in
pulmonary macrophages from smokers and COPD patients
(Polverino et al. 2010). We expanded on these observations
and investigated BAFF expression in the lungs of mice
exposed to cigarette smoke. We observed a marked increase
in BAFF levels in the bronchoalveolar lavage (BAL) of mice
following 1 week of cigarette smoke exposure (Fig. 1A).
Levels remained elevated in cigarette smoke-exposed ani-
mals exposed for 8 and 24 weeks (Fig. 1A). Similar obser-
vations were made in whole lung homogenates and
pulmonary macrophage lysates (Fig. 1B and C). Immunos-
taining showed that pulmonary macrophages are a major
source of BAFF following cigarette smoke exposure
(Fig. 1D). To extend our observations in mice, we analyzed
BAFF expression in a gene expression cohort of patients
with different smoking status as well as in BAL from cur-
rent smokers and nonsmokers. In humans, BAFF expres-
sion was significantly higher in smokers compared to
never-smokers, and remained elevated following smoking
cessation (Fig. 1E). Increased BAFF expression in smokers
was confirmed at the protein level in the BAL (Fig. 1F).
These data support the observation by Polverino et al.
(2010, 2015) and Seys et al. (2015) that BAFF expression is
increased in the lungs of smokers and shows that this
response is conserved between humans and mice.
BAFF induces IgM production by splenic and
lung B cells ex vivo
As we observed a marked elevation of BAFF following
cigarette smoke exposure, and given the role of BAFF in
2016 | Vol. 4 | Iss. 24 | e13057
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activating B cells, we sought to investigate whether BAFF
was sufficient to induce antibody production by B cells.
We found that stimulation of B cells with recombinant
BAFF induced a dose-dependent release of IgM from pri-
mary splenic (Fig. 2A) and lung B cells (Fig. 2B). This
supports the idea that elevation of BAFF in the lungs con-
tributes to local production of antibodies and, potentially,
autoantibodies.
BAFF neutralization attenuates TLT
formation and pulmonary antinuclear
autoantibody production in response to
chronic cigarette smoke exposure
Chronic cigarette smoking induces, in humans and mice,
the formation of TLTs and ANA (Hogg et al. 2004;
Morissette et al. 2014). To assess the role of BAFF in the
formation of TLTs and production of ANA, we exposed
BALB/c mice to cigarette smoke or room air for 24 weeks
and blocked BAFF using BAFFR-Fc during the last
12 weeks of exposure (Fig. 3A). A group of mice treated
with BAFFR-Fc was left untreated for another 8 weeks
after their last exposure to cigarette smoke as a treatment
cessation control (Fig. 3A). As we have previously
reported that both TLT and ANA normally persist follow-
ing smoking cessation in mice that were exposed to cigar-
ette smoke for 24 weeks; we did not include additional
cessation control groups (Morissette et al. 2014). Com-
pared to animals treated with the isotype control, mice
that received the BAFFR-Fc had significantly fewer pul-
monary TLTs (Fig. 3B, C and D), as shown by H&E, and
decreased B cells, as shown by flow cytometry (Fig. 4A).
We also observed lower levels of ANAs in the BAL
(Fig. 3E). Interestingly, compared to BAFFR-Fc-treated
mice exposed to cigarette smoke for 24 weeks, there was
Figure 1. Cigarette smoking leads to an increase in pulmonary B-cell activating factor (BAFF) levels with pulmonary macrophages as a major
source. Female BALB/c mice were exposed to room air (RA) or cigarette smoke (CS or Cig. Smoke) for 4 days, 8 weeks, or 24 weeks. (A) BAFF
expression in the bronchoalveolar lavage fluid (BALF). Data show mean  SEM, n = 5/group. (B and C) Representative western blots and
quantification of BAFF protein expression in whole lung homogenates and pulmonary macrophage lysates following 4 days of CS exposure. (D)
BAFF localization was assessed by immunohistochemistry in the lungs of mice exposed to RA or CS for 4 days. (E) mRNA levels were assessed
in resected lung tissues from nonsmokers (NonSm), active smokers (ActSm), and ex-smokers (ExSm) using gene arrays. (F) BAFF protein levels
were measured by ELISA in the BALF of nonsmokers and current smokers. *P < 0.05; ***P < 0.001.
Figure 2. B-cell activating factor (BAFF) induces antibody
production by lung and splenic B cells. B cells were isolated from
the (A) spleen and the (B) lungs of female BALB/c mice and
stimulated ex vivo for 3 days with recombinant mouse BAFF
(rmBAFF). IgM production was assessed in cell supernatants by
ELISA. Data show mean  SEM, n = 5/group.; *P < 0.05;
***P < 0.001.
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a slight increase in the number of pulmonary TLTs in
BAFFR-Fc-treated mice following 8 weeks of smoking and
treatment cessation; however, BAL ANA levels remained
unchanged. Altogether, these data show that BAFF block-
ade prevented smoke-induced pulmonary TLT formation
and ANA production when delivered during chronic
cigarette smoke exposure.
BAFF blockade reduces TLT and pulmonary
antinuclear autoantibodies following
smoking cessation
Given that BAFF blockade prevented the formation of
TLT and ANA induced by chronic cigarette smoke
exposure, we next investigated whether BAFF blockade
was able to resolve established TLTs and attenuate ANA
levels in the lungs following smoking cessation. To this
end, we exposed BALB/c mice to cigarette smoke or room
air for 24 weeks and administered BAFFR-Fc for 4 weeks
after the last smoke exposure (Fig. 5A). A group of ani-
mals were rested for an additional 8 weeks to investigate
if the effects of BAFFR-Fc persisted following treatment
cessation (Fig. 5A). Compared to animals treated with the
isotype control, mice that received the BAFFR-Fc had sig-
nificantly less pulmonary TLTs, as shown in H&E-stained
lung tissues (Fig. 5B, C, and E), and had decreased lung
B cells, as assessed by IHC (Fig. 5D) and flow cytometry







Figure 3. B-cell activating factor (BAFF) is critical for the formation of tertiary lymphoid tissues and antinuclear antibodies. (A) Female BALB/c
mice were exposed to room air (RA) or cigarette smoke (CS) for 24 weeks. BAFFR-Fc or isotype control was administered intraperitoneally twice
a week over the last 12 weeks of CS exposure. Groups of mice were killed 16 h after the last smoke exposure or after 8 weeks of smoking
cessation. Representative hematoxylin and eosin (H&E)-stained lung tissue sections are shown in (B) 16x and (C) 200x magnification. (D) B-cell
(B220+) localization in lung tissue (200x) assessed by immunohistochemistry. (E) Quantification of pulmonary TLT. (F) ANA levels in the
bronchoalveolar lavage fluid (BALF). Data represent mean  SEM, n = 5/group.; **P < 0.01; ***P < 0.001.
2016 | Vol. 4 | Iss. 24 | e13057
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the BALF (Fig. 5E). Moreover, BAFF-Fc-treated mice that
were left untreated for an additional 8 weeks had only a
slight increase in pulmonary TLTs, but no increase in
BAL ANA levels. These data suggest that a BAFF blockade
resolved established TLTs and attenuated increased ANA
levels, and that these effects persisted following treatment
cessation.
BAFF blockade reduces lung neutrophilia
following smoking cessation
Cigarette smoke exposure elicits an innate immune
inflammatory response that does not fully resolve follow-
ing smoking cessation (Willemse et al. 2004; Morissette
et al. 2014). Therefore, we investigated whether BAFF
blockade, and its associated reduction in TLTs and ANAs,
impacted inflammatory processes in the lungs. We found
that BAFFR-Fc administration during cigarette smoke
exposure had no effect on BAL total cell, mononuclear
cell, and neutrophil numbers (Fig. 6A). Of note, BAFFR-
Fc administration following smoking cessation signifi-
cantly reduced BAL neutrophils, and we observed a trend
toward reduced BAL total cell number (P = 0.051)
(Fig. 6B). These data suggest that BAFF blockade follow-
ing smoking cessation may promote the resolution of
lung inflammatory processes that would otherwise persist.
Discussion
The adaptive immune system has received recent atten-
tion for its potential role in the pathogenesis of COPD.
Of particular interest are the presence of autoantibodies
and the formation of TLTs in the lungs of COPD patients
and mice chronically exposed to cigarette smoke. The
objective of this study was to investigate whether BAFF, a
potent B-cell activator, contributed to the production of
autoantibodies and the formation of TLT in response to
cigarette smoke exposure.
Figure 4. Impact of BAFFR-Fc treatment on lung and spleen B- and T-cell populations. (A) Female BALB/c mice were exposed to room air
(open bars) or cigarette smoke (solid bars) for 24 weeks. BAFFR-Fc or isotype control was administered intraperitoneally twice a week over the
last 12 weeks of cigarette smoke exposure. (B) Female BALB/c mice were exposed to room air (open bars) or cigarette smoke (black bars) for
24 weeks. Following smoking cessation, BAFFR-Fc or isotype control was administered intraperitoneally for 4 weeks prior to killing. Single-cell
suspensions from the lungs and spleens were analyzed by flow cytometry. Data show B cells, CD4 T cells, and CD8 T cells as percent of the
total singlets (mean  SEM, n = 5/group). Bars with different superscripts are significantly different from each other and bars with the same
superscript do not differ significantly.
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Pulmonary BAFF expression and function was assessed
in a well-characterized mouse model of cigarette smoke
exposure (Gaschler et al. 2008; Botelho et al. 2010). We
previously reported elevated levels of autoantibodies fol-
lowing 24 weeks of smoke exposure that persisted follow-
ing smoking cessation, and coincided with the formation
of TLT in the lungs (Morissette et al. 2014). We utilized
BAFFR-Fc to block BAFF, using several different experi-
mental protocols, to investigate the function of BAFF in
the context of cigarette smoke exposure as well as follow-
ing smoking cessation. To validate our observations in
mice, we analyzed BAFF expression in a human gene
expression cohort and BAL samples from nonsmokers,
current smokers, and ex-smokers. The gene expression
cohort has previously been described in detail (Bosse
et al. 2012).
We observed rapid and sustained increase in soluble
BAFF expression in the BAL of cigarette smoke-exposed
mice. These findings suggest that induction of BAFF is
part of an early response to cigarette smoke exposure.
Similarly to Polverino et al. (2010), we found pulmonary
macrophages to be the main source of increased BAFF
expression in mice; however, other cells may also produce
BAFF in the lungs. Both mouse and human data showed
that pulmonary BAFF levels were increased following







Figure 5. B-cell activating factor (BAFF) neutralization resolves established tertiary lymphoid tissues and antinuclear antibody responses. (A)
Female BALB/c mice were exposed to room air or cigarette smoke for 24 weeks. Following smoking cessation, BAFFR-Fc or isotype control was
administered intraperitoneally twice a week for 4 weeks prior to killing. A group of mice that were smoke-exposed and received BAFFR-Fc
treatment underwent an additional 8 weeks of no treatment or smoke exposure prior to killing. Representative hematoxylin and eosin (H&E)-
stained lung tissue sections at (B) 16x and (C) 200x magnification are shown. (D) B-cell (B220) localization in lung tissue (200x). (E)
Quantification of pulmonary TLT in lung tissue and (F) ANA levels in the bronchoalveolar lavage fluid (BALF). Data represent mean  SEM,
n = 5/group.; **P < 0.01; ***P < 0.001.
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BAFF expression is not solely linked to COPD. While we
observed increased BAFF levels within days of cigarette
smoke exposure, autoantibodies were only measurable
after 8 weeks of exposure. Mechanisms that contribute to
this delay in the production of autoantibodies are cur-
rently not understood and remain to be elucidated.
BAFF is a potent regulator of B-cell activation Mackay
and Schneider (2009), hence, our observation that BAFF
induced antibody production by primary lung B cells sug-
gests that increased expression of BAFF following cigarette
smoke exposure may contribute to the production of
autoantibodies in vivo. This is in line with the observa-
tion that BAFF overexpression induces an autoimmune
phenotype in mice characterized by increased autoanti-
bodies against antinuclear targets (Thorn et al. 2010). We
are the first to show that BAFF blockade prevented local
production of autoantibodies in the lungs of cigarette
smoke-exposed mice. In addition, BAFF blockade attenu-
ated TLT formation, while having no effect on macro-
phage and neutrophil counts in the BAL. This latter
observation is in agreement with Seys et al. (2015) using
BAFF-Fc, as well as Bracke et al. (2013) using CXCL13
blockade. Both these interventions prevented TLT forma-
tion, but had no effect on inflammatory read-outs. In
contrast, decreased inflammation was observed in the
study by Seys et al. (2015) when BAFFR-Fc administra-
tion was initiated at the same time as smoke exposure.
While of interest, this experimental approach is not clini-
cally applicable given that therapeutic interventions will
likely be initiated after years of smoking. Taken together,
these findings suggest that prevention of autoantibody
production and TLT formation may have little impact on
the innate inflammatory process induced by cigarette
smoke exposure.
Smoking cessation is the most important clinical inter-
vention to prevent the development of smoking-related
diseases, such as COPD. To model the impact of BAFF-
targeted interventions following smoking cessation, we
exposed mice to cigarette smoke for 24 weeks and initi-
ated BAFF blockade after smoking cessation. We
Figure 6. B-cell activating factor (BAFF) neutralization accelerates resolution of bronchoalveolar lavage (BAL) neutrophilia following smoking
cessation. (A) Female BALB/c mice were exposed to room air or cigarette smoke for 24 weeks. BAFFR-Fc or isotype control was administered
intraperitoneally twice a week over the last 12 weeks of cigarette smoke exposure. (B) Female BALB/c mice were exposed to room air or
cigarette smoke for 24 weeks. Following smoking cessation, BAFFR-Fc or isotype controls were administered intraperitoneally for 4 weeks prior
to killing. Data show total cell number, mononuclear cells, and neutrophils in the BAL. Data shown as differential cell counts (mean  SEM,
n = 5/group). NS, nonsignificant; *P < 0.05.
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
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previously reported increased numbers of TLT and ele-
vated levels of autoantibodies that persist following smok-
ing cessation in mice (Morissette et al. 2014). To the best
of our knowledge, this is the first intervention that
reduces TLTs and autoantibody levels in the lungs, and
accelerates resolution of neutrophilic inflammation fol-
lowing smoking cessation. These data suggest that block-
ing BAFF signaling may have maximal therapeutic
potential when administered in conjunction with smoking
cessation. Importantly, pulmonary autoantibody levels
remained at baseline even after BAFFR-Fc administration
was discontinued. This suggests that BAFF-blocking thera-
pies administered for only a short period of time may
have the ability to generate long-lasting beneficial effects,
if smoking is not resumed.
In conclusion, this manuscript shows the importance
of BAFF in the formation of TLT and the local
production of autoantibodies in response to chronic
cigarette smoke exposure. Therapeutic blockade of BAFF
was effective in preventing, as well as inducing the
resolution of TLTs and autoantibodies in the lungs.
Further investigations are required to better understand
the specific role of TLTs and autoantibodies in COPD
to fully justify the development of such targeted
interventions.
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